Hydrazine synthesis
    1.
    发明授权
    Hydrazine synthesis 失效
    肼合成

    公开(公告)号:US5274096A

    公开(公告)日:1993-12-28

    申请号:US852593

    申请日:1992-03-17

    IPC分类号: C07D215/14 C07D215/12

    CPC分类号: C07D215/14

    摘要: An improved synthesis is described for producing a quinolinylmethoxyphenyl hydrazine which is an intermediate in the preparation of quinolinylmethoxyindoles useful as inhibitors of leukotriene biosynthesis. The improved process eliminates two isolation steps and yields a product of high purity.

    摘要翻译: 描述了用于制备喹啉基甲氧基苯基肼的改进的合成物,其是制备用作白三烯生物合成抑制剂的喹啉基甲氧基吲哚的中间体。 改进的方法消除了两个分离步骤,并产生了高纯度的产物。

    Novel Crystalline Forms of Antidiabetic Compounds
    2.
    发明申请
    Novel Crystalline Forms of Antidiabetic Compounds 失效
    抗糖尿病化合物的新型结晶形式

    公开(公告)号:US20080221198A1

    公开(公告)日:2008-09-11

    申请号:US11885842

    申请日:2006-03-10

    CPC分类号: C07D209/12

    摘要: Novel crystalline forms of two indole compounds connected to phenoxyalkylcarboxylic acid groups are selective PPAR gamma partial agonists that are useful in the treatment of type 2 diabetes, hyperglycemia, obesity, dyslipidemia, and the metabolic syndrome. The novel crystal forms include a crystalline free acid dihydrate and crystalline free acid anhydrate of one compound and several crystalline forms of the free acid and the sodium salt of the second compound. The invention also relates to pharmaceutical compositions comprising these novel crystal forms, processes to prepare the crystal forms and their pharmaceutical compositions, and uses of the crystal forms in the treatment of type 2 diabetes and other PPAR gamma modulated diseases.

    摘要翻译: 与苯氧基烷基羧酸基团连接的两个吲哚化合物的新结晶形式是可用于治疗2型糖尿病,高血糖症,肥胖症,血脂异常和代谢综合征的选择性PPARγ部分激动剂。 新型晶体形式包括一种化合物的结晶游离酸二水合物和结晶游离酸酐,以及第二化合物的游离酸和钠盐的几种结晶形式。 本发明还涉及包含这些新晶体形式的药物组合物,制备晶体形式的方法及其药物组合物,以及晶型用于治疗2型糖尿病和其它PPARγ调节疾病的用途。

    Crystalline forms of antidiabetic compounds
    3.
    发明授权
    Crystalline forms of antidiabetic compounds 失效
    抗糖尿病化合物的结晶形式

    公开(公告)号:US07683092B2

    公开(公告)日:2010-03-23

    申请号:US11885842

    申请日:2006-03-10

    IPC分类号: A61K31/404 C07D209/18

    CPC分类号: C07D209/12

    摘要: Novel crystalline forms of two indole compounds connected to phenoxyalkylcarboxylic acid groups are selective PPAR gamma partial agonists that are useful in the treatment of type 2 diabetes, hyperglycemia, obesity, dyslipidemia, and the metabolic syndrome. The novel crystal forms include a crystalline free acid dihydrate and crystalline free acid anhydrate of one compound and several crystalline forms of the free acid and the sodium salt of the second compound. The invention also relates to pharmaceutical compositions comprising these novel crystal forms, processes to prepare the crystal forms and their pharmaceutical compositions, and uses of the crystal forms in the treatment of type 2 diabetes and other PPAR gamma modulated diseases.

    摘要翻译: 与苯氧基烷基羧酸基团连接的两个吲哚化合物的新结晶形式是可用于治疗2型糖尿病,高血糖症,肥胖症,血脂异常和代谢综合征的选择性PPARγ部分激动剂。 新型晶体形式包括一种化合物的结晶游离酸二水合物和结晶游离酸酐,以及第二化合物的游离酸和钠盐的几种结晶形式。 本发明还涉及包含这些新晶体形式的药物组合物,制备晶体形式的方法及其药物组合物,以及晶型用于治疗2型糖尿病和其它PPARγ调节疾病的用途。

    Process for preparing fibrinogen receptor antagonists
    9.
    发明授权
    Process for preparing fibrinogen receptor antagonists 失效
    制备纤维蛋白原受体拮抗剂的方法

    公开(公告)号:US5312923A

    公开(公告)日:1994-05-17

    申请号:US17922

    申请日:1993-02-16

    CPC分类号: C07D213/30 C07D211/22

    摘要: The invention is a highly efficient synthesis for making compounds of the formula: ##STR1## wherein: R.sup.1 is a six membered saturated or unsaturated heterocyclic ring containing one or two heteroatoms wherein the heteroatoms are N; or NR.sup.6, wherein R.sup.6 is H or C.sub.1-10 alkyl;m is an integer from two to six; andR.sup.4 is aryl, C.sub.1-10 alkyl, or C.sub.4-10 aralkyl.

    摘要翻译: 本发明是制备下式的化合物的高效合成:其中:R1是含有一个或两个杂原子的六元饱和或不饱和杂环,其中杂原子是N; 或NR6,其中R6是H或C1-10烷基; m是二至六的整数; 和R 4是芳基,C 1-10烷基或C 4-10芳烷基。